The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer.
Claudette G
CG
Varricchio
Jeff A
JA
Sloan
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D017326:Clinical Trials, Phase III as Topic; D000068256:Darbepoetin alfa; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D016896:Treatment Outcome
D004921:Erythropoietin; D000068256:Darbepoetin alfa